Catalent (CTLT) Prices Common Share Offering for Gross Proceeds of Approx. $500M

After-Hours Stock Movers 02/03: (CTIC) (VSTM) (PCG) Higher; (RMTI) (EZPW) (GOOGL) Lower (more...)

February 3, 2020 5:58 PM EST

Today's After-Hours Stock Movers

CTI BioPharma Corp. (NASDAQ: CTIC) 18.2% HIGHER; adds to intra-day gains.

Rockwell Medical, Inc. (Nasdaq: RMTI) 13.7% LOWER; announced an underwritten public offering of its common stock. In addition, Rockwell Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

EZCORP (NASDAQ:... More

Catalent (CTLT) Announces $500M Public Offering of Common Stock

February 3, 2020 4:13 PM EST

Catalent, Inc. (Catalent) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has launched an underwritten public offering (the Offering) of $500 million of its common stock. In... More

Catalent (CTLT) PT Raised to $75 at JPMorgan, Following Earnings

February 3, 2020 3:09 PM EST

JPMorgan raised its price target on Catalent (NYSE: CTLT) to $75.00 (from $65.00) while maintaining a Overweight rating.

... More

Orgenesis (ORGS) Confirms Agreement for Sale of Masthercell Global

February 3, 2020 7:37 AM EST

Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell Global, Inc., a contract development manufacturing organization (CDMO) subsidiary of Orgenesis backed by Great Point Partners and SFPI-FPIM. Orgenesis anticipates that it will receive proceeds of approximately $127 million resulting from the... More

Catalent (CTLT) to Acquire MaSTherCell Global for $315 Million

February 3, 2020 7:36 AM EST

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ: ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.

MaSTherCell extends our leadership position in the... More

Catalent (CTLT) Tops Q2 EPS by 1c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

February 3, 2020 7:32 AM EST

Catalent (NYSE: CTLT) reported Q2 EPS of $0.45, $0.01 better than the analyst estimate of $0.44. Revenue for the quarter came in at $721.4 million versus the consensus estimate of $698.52 million.

Q2'20 revenue of $721.4 million increased 16% as-reported, or 17% in constant currency, from Q2'19.Accelerated growth in the Biologics segment. Solid organic growth in the Softgel and Oral Technologies and Clinical Supply Services segments more than offset decline in the Oral and Specialty Delivery segment.Announcing further expansion of Biologics footprint with agreement to acquire MaSTherCell, a leading cell therapy development and manufacturing... More